Opendata, web and dolomites

FORECEE SIGNED

Female cancer prediction using cervical omics to individualise screening and prevention

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FORECEE project word cloud

Explore the words cloud of the FORECEE project. It provides you a very rough idea of what is the project "FORECEE" about.

while    substantially    p4    invasive    personalised    virus    exposure    ethical    interaction    opportunity    forecee    recommendations    decision    excellent    communication    cervical    behavioural    progressed    prevent    hormonal    sensitive    agent    accessibility    cancers    trigger    identification    abundant    uuml    cells    personalized    genome    economics    hormone    output    readout    pipeline    lifetime    preventive    environmental    examine    dna    progression    individuals    translation    predictive    llerian    quality    effectiveness    smear    female    omics    technologies    progress    ideal    breast    rapid    risk    collected    clinically    disciplinary    made    prediction    utilise    prevention    source    window    cell    tandem    strategy    screening    tool    papilloma    individual    infection    origin    health    causal    ovarian    stakeholder    direct    tract    experts    benefit    metagenome    groups    halt    cancer    participatory    social    oncology    public    medicine    interventions    understand    endometrial    recording    aligned    enabled    clinical    epigenome    translate       human    team   

Project "FORECEE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.forecee.eu
 Total cost 7˙994˙746 €
 EC max contribution 7˙994˙746 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-PHC-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 3˙890˙699.00
2    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 711˙182.00
3    Eurofins Genomics Europe Sequencing GmbH DE (KONSTANZ) participant 558˙970.00
4    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 557˙866.00
5    ONCOTYROL-CENTER FOR PERSONALIZED CANCER MEDICINE GMBH AT (INNSBRUCK) participant 498˙440.00
6    UNIVERZITA KARLOVA CZ (PRAHA 1) participant 426˙520.00
7    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 299˙200.00
8    HELSE BERGEN HF*HAUKELAND UNIVERSITY HOSPITAL NO (BERGEN) participant 269˙697.00
9    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 248˙987.00
10    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER UK (LONDON) participant 210˙077.00
11    ISTITUTO EUROPEO DI ONCOLOGIA SRL IT (MILANO) participant 160˙500.00
12    EURAM LIMITED UK (LINCOLN) participant 83˙679.00
13    UNIVERSITY HOSPITALS SOUTHAMPTON NHS FOUNDATION TRUST UK (SOUTHAMPTON) participant 78˙926.00
14    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 0.00

Map

 Project objective

While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (cervical smear) and availability of a test for the causal agent (human papilloma virus); together these enable identification of high risk individuals and interventions to prevent infection or halt progression to invasive cancer. Our consortium has developed an exciting opportunity to utilise clinically abundant cervical cells in tandem with a multi-omics enabled (genome, epigenome, metagenome) analysis pipeline to understand an individual’s risk of developing a female specific cancer and to direct a personalised screening and prevention strategy. Cervical cells – currently collected within cervical cancer screening – provide an ideal window into other female specific cancers because they are (i) an excellent non-invasive source of high quality DNA, (ii) provide a readout for environmental exposure, (iii) are part of the Müllerian tract and (iv) are hormone sensitive, recording (via the epigenome) various hormonal conditions over a lifetime that trigger cancer development. The FORECEE project is aligned with the novel concept of “P4 Medicine” (predictive, preventive, personalized, and participatory): it aims to translate the risk prediction tool’s output into personalised recommendations for screening and prevention of female cancers. Our consortium comprises a multi-disciplinary team of experts in clinical oncology, risk-benefit communication, omics technologies, decision analysis, health economics and public health. We will examine the effectiveness of the proposed cervical cell omics analysis method and investigate the legal, social, ethical and behavioural issues related to implementation of the risk prediction tool, through direct interaction with stakeholder groups, to ensure its rapid translation into clinical practice across Europe.

 Deliverables

List of deliverables.
Multimedia presentation available Websites, patent fillings, videos etc. 2019-12-09 18:06:10
Leaflet and results from survey and public workshop results Documents, reports 2019-12-09 18:06:10
Formal presentation to the ESGO patient advocacy group (ENGAGe) Websites, patent fillings, videos etc. 2019-12-09 18:06:09
Project website Websites, patent fillings, videos etc. 2019-12-09 18:06:09
Review on decision-analytic cost-effectiveness Documents, reports 2019-12-09 18:06:09

Take a look to the deliverables list in detail:  detailed list of FORECEE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Maaike Alblas, Maartje Schermer, Yvonne Vergouwe, Ineke Bolt
Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?
published pages: 14, ISSN: 2075-4426, DOI: 10.3390/jpm9010014
Journal of Personalized Medicine 9/1 2019-12-09
2018 Odette Wegwarth, Martin Widschwendter, David Cibula, Karin Sundström, Rosalba Portuesi, Ines Lein, Felix G Rebitschek
What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries
published pages: e023789, ISSN: 2044-6055, DOI: 10.1136/bmjopen-2018-023789
BMJ Open 8/12 2019-12-09
2018 Emmanuelle Lévesque, Emily Kirby, Ineke Bolt, Bartha Maria Knoppers, Inez de Beaufort, Nora Pashayan, Martin Widschwendter
Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women’s Cancer: Points to Consider
published pages: 1-8, ISSN: 1662-4246, DOI: 10.1159/000492663
Public Health Genomics 2019-12-09
2018 Charles Dupras, Lingqiao Song, Katie M. Saulnier, Yann Joly
Epigenetic Discrimination: Emerging Applications of Epigenetics Pointing to the Limitations of Policies Against Genetic Discrimination
published pages: , ISSN: 1664-8021, DOI: 10.3389/fgene.2018.00202
Frontiers in Genetics 9 2019-12-09
2018 Martin Widschwendter, Allison Jones, Iona Evans, Daniel Reisel, Joakim Dillner, Karin Sundström, Ewout W. Steyerberg, Yvonne Vergouwe, Odette Wegwarth, Felix G. Rebitschek, Uwe Siebert, Gaby Sroczynski, Inez D. de Beaufort, Ineke Bolt, David Cibula, Michal Zikan, Line Bjørge, Nicoletta Colombo, Nadia Harbeck, Frank Dudbridge, Anne-Marie Tasse, Bartha M. Knoppers, Yann Joly, Andrew E. Teschendorff, Nora Pashayan
Epigenome-based cancer risk prediction: rationale, opportunities and challenges
published pages: 292-309, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2018.30
Nature Reviews Clinical Oncology 15/5 2019-12-09
2018 Maaike Alblas, Kimberley B. Velt, Nora Pashayan, Martin Widschwendter, Ewout W. Steyerberg, Yvonne Vergouwe
Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review
published pages: 92-99, ISSN: 1040-8428, DOI: 10.1016/j.critrevonc.2018.03.023
Critical Reviews in Oncology/Hematology 126 2019-12-09
2016 Vit Weinberger, Marketa Bednarikova, David Cibula, Michal Zikan
Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management
published pages: 1311-1321, ISSN: 1473-7140, DOI: 10.1080/14737140.2016.1247699
Expert Review of Anticancer Therapy 16/12 2019-12-09
2016 Nora Pashayan, Daniel Reisel, Martin Widschwendter
Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges
published pages: 93-95, ISSN: 1741-0541, DOI: 10.2217/pme.15.53
Personalized Medicine 13/2 2019-12-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FORECEE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FORECEE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  

ONCOBIOME (2019)

Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Read More